Improved renal function during chronic lisinopril treatment in moderate to severe primary hypertension

Journal of Cardiovascular Pharmacology
A G DupontR O Six

Abstract

The effect of the converting enzyme inhibitor lisinopril on renal and cardiac hemodynamics was studied in patients with moderate to severe primary hypertension, in a multicenter, double-blind, randomized clinical trial comparing the antihypertensive effect of lisinopril (LIS) and nifedipine (NIF). After a 2 week placebo run-in period, 15 patients were randomized in a 2:1 ratio to receive either LIS (20-80 mg q.d., n = 10) or NIF (20-40 mg b.i.d., n = 5). LIS significantly reduced blood pressure (BP) without changing heart rate or cardiac output. LIS significantly increased renal blood flow; glomerular filtration rate (GFR) was not changed. It can be concluded that LIS is an effective antihypertensive agent with a favorable renal hemodynamic profile.

Citations

Oct 1, 1992·Cardiovascular Drugs and Therapy·J P DegauteP Vandepapeliere
Mar 15, 1990·Journal of the American College of Cardiology·B E Strauer
Aug 16, 2016·Frontiers in Physiology·Holly Digne-MalcolmKeith L Dorrington
Sep 10, 1998·Journal of Cardiovascular Pharmacology·R R Ruffolo, G Z Feuerstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.